Abstract
The 3-weekly combination of trastuzumab and paclitaxel has been approved for the treatment of advanced breast cancer based on a large pivotal study. However, mono and combination chemotherapy trials suggest that weekly paclitaxel has a better therapeutic index, especially in the palliative setting. The present trial examined the efficacy and safety of weekly paclitaxel over a limited duration combined with continued trastuzumab in HER2+ patients. Patients with histologically confirmed metastatic breast cancer overexpressing HER2 were eligible if pretreated with anthracycline in either the adjuvant or palliative setting. Treatment consisted of weekly trastuzumab (2 mg/kg/week for up to one year after a loading dose of 4 mg/kg in week 1) and paclitaxel (90 mg/m², administered in weeks 1-6 and 8-13). Twenty-seven German centers enrolled 121 patients. The median number of metastatic sites was two (range 1-5); 38% of patients had received chemotherapy for advanced disease. After a median 42 weeks of trastuzumab treatment, limited by disease progression in roughly half the patients, a best objective response rate (complete response + partial response) of 76% was achieved, including complete remissions in 29%. 74% of patients lived wi...Continue Reading
References
Jan 9, 1987·Science·D J SlamonW L McGuire
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BaselgaL Norton
Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A D SeidmanL Norton
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A CobleighD J Slamon
Mar 15, 2001·The New England Journal of Medicine·D J SlamonL Norton
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A D SeidmanC A Hudis
Nov 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E A PerezR Patel
Feb 2, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G FountzilasD Skarlos
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SeidmanDeborah Keefe
Jan 8, 2004·British Journal of Cancer·S GoriM Tonato
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard BurrisJohn Hainsworth
May 20, 2004·Journal of the National Cancer Institute·Mark D PegramDennis J Slamon
May 25, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michel MartyJean-Marc Extra
Dec 31, 2005·Clinical Breast Cancer·Edith A PerezRobert B Jenkins
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas RobertDennis Slamon
Jul 6, 2007·The New England Journal of Medicine·Clifford A Hudis
Apr 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew D SeidmanClifford Hudis
Jun 3, 2008·The Oncologist·Karen Bullock, Kimberly Blackwell
Feb 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael UntchHans-Joachim Lück
Apr 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alessandra GennariPaolo Bruzzi
Citations
Jul 12, 2014·BioMed Research International·Mohamed HassanNoriaki Sakuragi
Dec 30, 2015·Internal and Emergency Medicine·Stefania MantarroLorenzo Moja
Dec 10, 2014·BMC Cancer·Christian JackischAxel Hinke
Dec 17, 2014·BMC Cancer·Gianmaria MioloRiccardo Dolcetti
Jun 25, 2014·Hospital Pharmacy·Thomas LehmannJ Aubrey Waddell
Mar 19, 2013·Cancer Letters·Donghai JiangWeimin Fan
Dec 16, 2017·Cancer Chemotherapy and Pharmacology·Xinna ZhouH Kim Lyerly
Sep 23, 2016·Breast Cancer Research and Treatment·Vakaramoko DiabyAlberto J Montero
Nov 21, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Vakaramoko DiabyAskal Ali